TY - JOUR
T1 - Peripheral levels of BDNF and opiate-use disorder: Literature review and update
AU - Palma-Álvarez, Raul Felipe
AU - Ros-Cucurull, Elena
AU - Amaro-Hosey, Kristopher
AU - Rodriguez-Cintas, Laia
AU - Grau-López, Lara
AU - Corominas-Roso, Margarida
AU - Sánchez-Mora, Cristina
AU - Roncero, Carlos
PY - 2017/7/1
Y1 - 2017/7/1
N2 - © 2017 Walter de Gruyter GmbH, Berlin/Boston 2017. Several neurobiological factors are related to opiate-use disorder (OUD), and among them, neurotrophins have a relevant role. Brain-derived neurotrophic factor (BDNF) is a central neurotrophin involved in many neuronal processes, and it has been related to several psychiatric diseases and addictive disorders. BDNF can be measured in plasma and serum; its levels may reflect BDNF concentrations in the central nervous system (CNS) and, indirectly, CNS processes. Hence, peripheral BDNF could be a biomarker in clinical practice. This manuscript explores the findings about peripheral BDNF and OUD in humans. Opiates induce neurotoxicity in the CNS, which may be correlated with modifications in BDNF expression. Thus, basal levels of peripheral BDNF in OUD patients may be altered, which could be modified with abstinence. Also, opiates may modify epigenetic processes that may be associated with peripheral concentrations of BDNF, and in this line, withdrawal could reflect recovering processes in the CNS. Additionally, treatment modifies the peripheral concentrations of BDNF, but the clinical implications of those changes are yet not elucidated. No specific conclusion can be performed and more investigation in this area is necessary to elucidate the real potential of peripheral BDNF as a biomarker.
AB - © 2017 Walter de Gruyter GmbH, Berlin/Boston 2017. Several neurobiological factors are related to opiate-use disorder (OUD), and among them, neurotrophins have a relevant role. Brain-derived neurotrophic factor (BDNF) is a central neurotrophin involved in many neuronal processes, and it has been related to several psychiatric diseases and addictive disorders. BDNF can be measured in plasma and serum; its levels may reflect BDNF concentrations in the central nervous system (CNS) and, indirectly, CNS processes. Hence, peripheral BDNF could be a biomarker in clinical practice. This manuscript explores the findings about peripheral BDNF and OUD in humans. Opiates induce neurotoxicity in the CNS, which may be correlated with modifications in BDNF expression. Thus, basal levels of peripheral BDNF in OUD patients may be altered, which could be modified with abstinence. Also, opiates may modify epigenetic processes that may be associated with peripheral concentrations of BDNF, and in this line, withdrawal could reflect recovering processes in the CNS. Additionally, treatment modifies the peripheral concentrations of BDNF, but the clinical implications of those changes are yet not elucidated. No specific conclusion can be performed and more investigation in this area is necessary to elucidate the real potential of peripheral BDNF as a biomarker.
KW - BDNF
KW - biomarker
KW - heroin
KW - opiate
KW - opiate-use disorder
U2 - 10.1515/revneuro-2016-0078
DO - 10.1515/revneuro-2016-0078
M3 - Article
VL - 28
SP - 499
EP - 508
JO - Reviews in the Neurosciences
JF - Reviews in the Neurosciences
SN - 0334-1763
IS - 5
ER -